Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-03-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于续聘公司2023年度财务审计机构及内控审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's financial audit and internal control audit firm for the year 2023. It details the qualifications, independence, and integrity of the proposed audit firm, the audit fees, and the approval process by the board and independent directors. It does not contain actual financial statements or audit reports but rather informs shareholders and the public about the intention to appoint the audit firm, pending shareholder approval. The document length is 3728 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit firm appointment and audit-related information, but it is not a full annual report or audit report itself. However, given the short length and nature as an announcement of appointment, it aligns more closely with an Audit Report / Information (AR) rather than a full Annual Report (10-K) or Report Publication Announcement (RPA). FY 2023
2023-03-29 Chinese
长春百克生物科技股份公司2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2022 by Changchun Baike Biotechnology Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification standards, and rectification status. The content is detailed and specific to internal control evaluation rather than a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on internal control evaluation. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles and internal control evaluations, excluding full annual reports. FY 2022
2023-03-29 Chinese
长春百克生物科技股份公司2022年度控股股东及其他关联方占用资金情况审核报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report on the situation of funds occupied by controlling shareholders and other related parties for the year 2022. It is issued by a certified public accounting firm and includes an audit opinion, responsibilities of management and governance, and detailed financial data related to non-operating fund occupation and related party transactions. The document is not a full annual report but a standalone audit report focusing on a specific financial aspect, consistent with the definition of an Audit Report / Information (AR). The length of the document (7035 characters) and the detailed audit content support this classification rather than a brief announcement or a full annual report. FY 2022
2023-03-29 Chinese
长春百克生物科技股份公司2022年度内控审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of the company's internal control over financial reporting as of December 31, 2022. The content includes the auditor's responsibilities, the company's responsibilities, and an audit opinion on internal control effectiveness. The document is a standalone audit report focused on internal control, not a full annual report or financial statement. It does not appear to be a brief announcement or certification letter but a formal audit report. Therefore, it fits the category of Audit Report / Information (AR). The document length is 1962 characters, which is reasonable for an audit report and not just a short announcement.
2023-03-29 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司2022年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "持续督导跟踪报告" (Continuous Supervision Follow-up Report) issued by the sponsor (中信证券股份有限公司) for 长春百克生物科技股份公司 for the year 2022. It details the sponsor's ongoing supervision activities, compliance with regulatory requirements, risk assessments, financial data, R&D progress, and use of raised funds. The content is comprehensive and includes substantive financial data, risk disclosures, and operational updates. It is not a full annual report (10-K) but rather a regulatory continuous supervision report required for companies listed on the STAR Market (科创板) in China. This type of document aligns with the category of Audit Report / Information (AR), as it is a standalone regulatory report related to ongoing audit and supervision activities, not a full annual report or earnings release. The document length (14,494 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the best fitting classification is AR with high confidence. FY 2022
2023-03-29 Chinese
长春百克生物科技股份公司2022年年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" which translates to "2022 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes signatures from company officers and auditors, detailed financial tables, and comprehensive narrative sections typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-03-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.